Literature DB >> 19255606

Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.

John Craddock1, Helen E Heslop.   

Abstract

Entities:  

Year:  2008        PMID： 19255606      PMCID： PMC2390887          DOI： 10.1016/j.uct.2008.01.001

Source DB:  PubMed          Journal:  Update Cancer Ther        ISSN： 1872-115X


× No keyword cloud information.
  60 in total

1.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Authors:  S Gottschalk; C Y Ng; M Perez; C A Smith; C Sample; M K Brenner; H E Heslop; C M Rooney
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

2.  Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells.

Authors:  Patrizia Comoli; Rita Maccario; Franco Locatelli; Umberto Valente; Sabrina Basso; Alberto Garaventa; Paolo Tomà; Gerardo Botti; Giovanni Melioli; Fausto Baldanti; Arcangelo Nocera; Francesco Perfumo; Fabrizio Ginevri
Journal:  Am J Transplant       Date:  2005-06       Impact factor: 8.086

3.  Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

Authors:  Kristine Lacuesta; Elizabeth Buza; Hans Hauser; Laura Granville; Martin Pule; Greg Corboy; Milton Finegold; Heidi Weiss; Si Y Chen; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

4.  Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.

Authors:  Hyun-Il Cho; Young Seon Hong; Myung Ah Lee; Eun-Kyung Kim; Sung-Hee Yoon; Chun-Choo Kim; Tai-Gyu Kim
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

5.  Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.

Authors:  Martina A Sherritt; Mandvi Bharadwaj; Jacqueline M Burrows; Leanne E Morrison; Suzanne L Elliott; Joanne E Davis; Laurie M Kear; Richard E Slaughter; Scott C Bell; Andrew J Galbraith; Rajiv Khanna; Denis J Moss
Journal:  Transplantation       Date:  2003-05-15       Impact factor: 4.939

6.  The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Authors:  Catherine M Bollard; Karin C M Straathof; M Helen Huls; Alan Leen; Kristine Lacuesta; Alan Davis; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunother       Date:  2004 Jul-Aug       Impact factor: 4.456

7.  Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.

Authors:  Ayako Demachi-Okamura; Yoshinori Ito; Yoshiki Akatsuka; Kunio Tsujimura; Yasuo Morishima; Toshitada Takahashi; Kiyotaka Kuzushima
Journal:  Eur J Immunol       Date:  2006-03       Impact factor: 5.532

8.  Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.

Authors:  Qi Sun; Robert Burton; Vishnu Reddy; Kenneth G Lucas
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

9.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.

Authors:  Kui Shin Voo; Tihui Fu; Helen Y Wang; Judy Tellam; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Rong-Fu Wang
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307
View more
  6 in total

Review 1.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 2.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.

Authors:  Anna Bellizzi; Nicholas Ahye; Gauthami Jalagadugula; Hassen S Wollebo
Journal:  J Neuroimmune Pharmacol       Date:  2019-09-11       Impact factor: 4.147

Review 4.  The other side of the coin: Leveraging Epstein-Barr virus in research and therapy.

Authors:  Fenggang Yu; Wei Jian Tan; Yanan Lu; Paul A MacAry; Kwok Seng Loh
Journal:  Oral Oncol       Date:  2016-07-21       Impact factor: 5.337

Review 5.  T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies.

Authors:  Valérie Janelle; Jean-Sébastien Delisle
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 6.  Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target.

Authors:  Queenie Fernandes; Maysaloun Merhi; Afsheen Raza; Varghese Philipose Inchakalody; Nassima Abdelouahab; Abdul Rehman Zar Gul; Shahab Uddin; Said Dermime
Journal:  Front Oncol       Date:  2018-07-06       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.